Lonza to Invest in Mid-Scale Biologics, Cell Therapy Manufacturing
Lonza announces addition of mid-scale biologics manufacturing capacity and cell-therapy suites at Portsmouth, NH site.
Lonza Pharma & Biotech announced plans to add mid-scale mammalian capacity and cell-therapy suites at the company’s Portsmouth, NH facility. The investment was announced in a press statement on May 4, 2018.
The company plans to install multiple 6000-L bioreactors with construction expected to start in late 2018. The hybrid facility will feature full-suite process analytic technology, multi-variate analysis, and single-use technologies in an existing building.
Lonza also announced the installation of multiple cell-therapy suites at the Portsmouth site. In February 2018, the company identified Portsmouth as a clinical and commercial manufacturing center for cell therapies, providing customers access to facilities for Phase I through to commercial manufacturing in one location. The facility is expected to be operational by late 2018.
Source: Lonza Pharma & Biotech
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
